selective beta 2 (β2) adrenomimetic -bronchodilator

Pharmacological group: selective beta 2 (β2) adrenomimetic -bronchodilator.
Generic name: Salbutamol
Drug form: Tablets

Composition:
Salbutamol sulphate - 2,41mg. (corresponds to 2mg Salbutamol);
Salbutamol sulphate - 4,82mg. (corresponds to 4mg Salbutamol);
Aiding substances: Lactose, starch, microcrystalline cellulose, calcium or magnesium stearate.
Pharmacological operation:
Pharmacodynamics:
Salbutamol represents beta-adrenomimetic primary influence on β2 adrenoreceptors (being localized in bronchi, myometrium and blood vessels).
"Salbutamol Neo", with selective stimulation of bronchial β2 adrenoreceptors, causes relaxation of smooth muscles and expansion of bronchi, stops bronchospasm, increases the vital capacity of lungs. Renders weakly expressed positive chrono- and inotropic operation on a myocardium. Expands coronary vessels, practically doesn't reduce arterial pressure. Lowers, myometrium tone and contractility (tocolytic operation).
Pharmacokinetics:
Salbutamol is quickly absorbed from the gastrointestinal tract. Maximum concentration in blood serum is reached approximately in 2 hours.
The preparation metabolizes in the liver and is excreted in the form of metabolites. Salbutamol sulfate doesn't break up by lungs catechol-0-methyltransferase, by this reason it has long-term action.
Indication:
• Smooth muscles' spasm at time of bronchial asthma;
• Chronic spastic bronchitis;
• Lungs emphysema;